EGFR and head and neck squamous cell carcinoma: Our novel findings provide precise mechanistic insights into action of HDAC inhibitors by exploring the previously unrecognized function in interrupting the EGFR-Arf1 complex in HNSCC progression, which provide the rationale for further clinical applications of this strategy in patients with HNSCC.